CJC-1295 vs Tesamorelin: A GHRH-Analogue Comparison
A neutral research overview of two growth-hormone-releasing-hormone analogues studied in endocrine research models — structure, half-life, and research focus.
CJC-1295 and Tesamorelin are both growth-hormone-releasing-hormone (GHRH) analogues studied in endocrine research. They are compared because they act on the same research pathway — GHRH signalling — while differing in structure and studied half-life.
| CJC-1295 | Tesamorelin | |
|---|---|---|
| Class | GHRH analogue | GHRH analogue |
| Structure | Modified GHRH(1-29), often studied with Ipamorelin | Stabilised GHRH(1-44) analogue |
| Research focus | GH-secretion and hormonal-axis models | Endocrine and metabolic research models |
| Common pairing | Frequently studied with Ipamorelin | Studied as a single agent |
| Format | Lyophilised vial | Lyophilised vial |
CJC-1295 — research overview
CJC-1295 is a GHRH analogue studied in models of growth-hormone secretion, frequently examined in combination with Ipamorelin. See our note on CJC-1295 + Ipamorelin research.
Tesamorelin — research overview
Tesamorelin is a stabilised GHRH-analogue studied in endocrine and metabolic research models. See our overview of Tesamorelin GHRH research.
Key differences researchers note
Both target the GHRH pathway, but CJC-1295 is most often studied as part of a combination (with Ipamorelin), while Tesamorelin is typically studied as a single, stabilised analogue. Structural differences influence the studied duration of activity, which is a common variable in research designs comparing the two.
Research considerations
Both are third-party tested with a published Certificate of Analysis — verify a batch or read the Quality Report.
*Research use only. CJC-1295 and Tesamorelin are sold strictly for in vitro laboratory research and are not for human or veterinary use.*